QRG Capital Management Inc. Has $80.46 Million Stock Position in Johnson & Johnson $JNJ

Key Points

• QRG Capital raised its stake in Johnson & Johnson by 10.4% in Q4 to 388,781 shares worth about $80.46 million, making JNJ its 15th-largest holding (0.9% of the fund).
• JNJ slightly beat Q1 estimates with $2.70 EPS on $24.06 billion revenue and set FY‑2026 guidance of 11.45–11.65 EPS; the company also raised its quarterly dividend to $1.34 ($5.36 annual, ~2.4% yield).
• Recent pipeline wins (TREMFYA Phase 3, JNJ‑4804 Phase 2b, Ottava robot study) bolster long‑term prospects, but near‑term risks include CVS dropping Stelara from main formularies and at least one missed IBD trial creating commercial uncertainty.

QRG Capital Management Inc. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 388,781 shares of the company's stock after acquiring an additional 36,730 shares during the period. Johnson & Johnson comprises 0.9% of QRG Capital Management Inc.'s holdings, making the stock its 15th largest holding. QRG Capital Management Inc.'s holdings in Johnson & Johnson were worth $80,458,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Abich Financial Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at about $26,000. DecisionPoint Financial LLC boosted its holdings in Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company's stock valued at $30,000 after acquiring an additional 75 shares during the last quarter. Family CFO Inc acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $31,000. Stone House Investment Management LLC raised its holdings in Johnson & Johnson by 58.9% during the 4th quarter. Stone House Investment Management LLC now owns 197 shares of the company's stock worth $41,000 after purchasing an additional 73 shares during the last quarter. Finally, Semmax Financial Advisors Inc. lifted its position in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock worth $31,000 after purchasing an additional 72 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.5%

NYSE:JNJ opened at $224.47 on Thursday. Johnson & Johnson has a 12 month low of $146.12 and a 12 month high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $540.35 billion, a price-to-earnings ratio of 25.95, a PEG ratio of 2.21 and a beta of 0.27. The firm has a fifty day simple moving average of $238.07 and a two-hundred day simple moving average of $220.38.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to analysts' expectations of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business's revenue was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Analysts expect that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.4%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson's payout ratio is 60.12%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: TREMFYA showed statistically significant benefit in a Phase 3 study for perianal fistulizing Crohn’s disease — a meaningful clinical win that could expand TREMFYA’s IBD label and support long‑term sales growth in immunology. TREMFYA study press release
• Positive Sentiment: JNJ reported strong Phase 2b data for investigational co‑antibody JNJ‑4804 in refractory IBD (DUET studies), supporting advancement toward Phase 3 and adding pipeline optionality versus current therapies. JNJ‑4804 DUET data
• Positive Sentiment: Johnson & Johnson’s Ottava surgical robot reportedly met endpoints in a pivotal bariatric study — a promising signal for the company’s MedTech R&D and future device commercialization. Ottava study
• Neutral Sentiment: Market pieces and screeners continue to highlight JNJ as a Dividend King and a dividend‑income option (Fool, 247wallst, Zacks coverage), which supports steady investor demand from income-focused holders but is unlikely to move the stock dramatically by itself. Safer Dividend King article
• Neutral Sentiment: Broad reporting notes J&J is expanding its clinical pipeline across immunology, MedTech and AI initiatives — constructive for long‑term growth but mostly early‑stage in terms of revenue impact. Pipeline expansion article
• Negative Sentiment: CVS will drop J&J’s Stelara from its main formularies in favor of lower‑cost interchangeable biosimilars starting July 1 — a near‑term commercial headwind for Stelara sales and an obvious driver of downward pressure on the shares. CVS drops Stelara
• Negative Sentiment: Coverage notes mixed IBD results: while some J&J programs show promise, at least one trial missed its primary endpoint (coverage describes advancement “despite” a miss), creating short‑term uncertainty about timing/scale of benefits and raising questions for near‑term sales guidance. Stat News coverage

Analyst Ratings Changes

JNJ has been the subject of several recent analyst reports. Guggenheim increased their price objective on shares of Johnson & Johnson from $244.00 to $266.00 and gave the stock a "buy" rating in a research report on Monday, April 20th. Bank of America increased their price target on Johnson & Johnson from $253.00 to $254.00 and gave the stock a "neutral" rating in a report on Wednesday, April 15th. HSBC lifted their price objective on Johnson & Johnson from $265.00 to $280.00 and gave the stock a "buy" rating in a research report on Tuesday, March 17th. Argus upped their target price on Johnson & Johnson from $240.00 to $275.00 and gave the company a "buy" rating in a research report on Thursday, April 16th. Finally, The Goldman Sachs Group raised their target price on Johnson & Johnson from $265.00 to $275.00 and gave the stock a "buy" rating in a research note on Wednesday, April 15th. Eighteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $252.48.

Insider Buying and Selling

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 1,322 shares of the company's stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 30,142 shares of company stock valued at $7,360,528 in the last three months. Insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.